Current Trend in Pneumococcal Serotype Distribution in Asia

Cheng-Foh Le, Mohd Yasim Mohd Yusof and Shamala Devi Sekaran*

Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

Abstract

Asia is one of the continents in the world heavily impacted by pneumococcal diseases but yet the information on disease burden and serotype distribution remained largely unclear. The data is essentially needed to inform the burden of pneumococcal diseases as a priority public health concern among the Asian countries. The formulations of pneumococcal conjugate vaccines (PCV) included a number of prevailing serotypes in the Western world but geographical and temporal variations of vaccination effectiveness could be expected in Asia. This review focuses specifically on the most recent five years trend in serotype distributions from both invasive and non-invasive pneumococcal diseases in Asia. Other important features such as antimicrobial resistance and associated clones were also noted. All latest studies reported that complied with the scopes of this review were included and the serotyping data were extracted for comparison analysis between countries, regions, and to represent Asia as the whole. The most common serotypes detected in highest to lowest frequencies order are 19F, 14, 23F, 6B, 19A, 3, and 6A, accounted for approximate two third of the incidences. Heptavalent PCV (PCV7) is expected to cover half of the incidences with significant increment in efficacy with PCV13. East Asia, Southeast Asia, and West Asia have relatively similar serotype distributions though slight variations were observed. The more unique pattern is noted in South Asia region. Initiation of surveillance study in countries with no reporting data is needed. Continued surveillance involving nationwide or multinational collaborative networks need to be set up to enhance and standardize the reporting incidences.

Keywords: Streptococcus pneumonia; Asia; Serotype distribution; Pneumococcal conjugate vaccine; Pneumococcal disease; Clonal complex; Antimicrobial resistance

Abbreviations: PCV7: Heptavalent Pneumococcal Conjugate Vaccine; PCV10: Decavalent Pneumococcal Conjugate Vaccine; PCV13: Triskaivalent Pneumococcal Conjugate Vaccine; AOM: Acute Otitis Media; VT: Vaccine Serotype; NVT: Non-Vaccine Serotype; MDR: Multidrug Resistant; NIP: National Immunization Program

Introduction

Streptococcus pneumoniae is one of major human pathogens causing various major infections such as pneumonia, bacteremia, meningitis, and acute otitis media (AOM) worldwide [1-4]. In year 2005, the World Health Organization (WHO) estimated that out of the 1.6 million total deaths due to pneumococcal disease every year, 0.7 – 1 million were children <5 years of age [5]. To date, 93 distinct pneumococcal serotypes have been identified so far. Serotype 6C [6], 6D [7], and 11E [8] are the latest known serotypes and more are yet to be characterized. Nevertheless, only a limited set of serotypes are capable of causing infections [9-11]. Some serotype also display increase tendency in certain diseases. For instance, the most common serotypes detected in AOM were serotypes 19F, 23F, 19A, 6A, 6B, and 14 [12,13] while serotype 1, 5, and 7F were unusual in AOM.

The 23-valent pneumococcal polysaccharide vaccine (PPV23, Pneumovax) covers 23 pneumococcal serotypes and is able to induce protective immune responses in adults [14-17] though conflicting data has been reported [18]. However, the immune response is particularly poor in younger children <2 years of age and individual with underlying immunosuppressive conditions [19]. The maximal efficacy of PPV23 was estimated to be only 70% and revaccination might be needed in certain people as the antibody level begins to falls the following year after vaccination [20]. In February 2000, the heptavalent pneumococcal conjugate vaccine, PCV7 (PCV7, Prevnar) formulated with serotypes 4, 6B, 9V, 14, 18C, 19F, 23F was licensed in the United States and was later incorporated under the childhood vaccination programme in mid 2000 for all infants and children <2 years of age [21,22]. Those 24 – 59 months old who are at particular risks of pneumococcal invasive infections such as immunocompromised conditions (chronic heart diseases, chornic lung diseases), diabetes mellitus, sickle cell diseases, and human Immunodeficiency virus (HIV) infections were also recommended [21,22]. Each of the individual strain antigens (capsular polysaccharide) is conjugated to the nontoxic diphtheria proteins, CRM197 eliciting strong T-cell dependent immune responses and protective PCV7-specific antibodies level (>1 μg/ml specific antibody in 51 – 90% immunized children after 3 doses) in the children [21,23-26] and stimulation of T-cell memory [26]. No major safety issue is associated with PCV7 use though mild local reaction at the injection site and fever were noted [27-28]. Later, European countries such as Netherlands [29], Norway [30], and the United Kingdom [31,32] have also made PCV7 into routine immunization. This vaccine comprises seven of most common serotypes causing invasive pneumococcal disease (IPD) among young children in US and European countries, representing approximately 60 – 80% of the serotypes [5,28,33]. PCV10 and PCV13 were reported with mean increase in coverage of 7% and 16% respectively among the Europeans [34]. Up to May 2009, PCV7 was introduced in over 90 countries and incorporated under the National Immunization Program (NIP) of 36 countries in the world.

*Corresponding author: Shamala Devi Sekaran, Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia; Tel: 6-0379-675759; Fax: 6-0379-584844; E-mail: shamalamy@yahoo.com

Received October 20, 2011; Accepted December 13, 2011; Published December 16, 2011

Citation: Le C, Yusof MYM, Sekaran SD (2011) Current Trend in Pneumococcal Serotype Distribution in Asia. J Vaccines Vaccin 2:001. doi:10.4172/2157-7560.S2-001

Copyright: © 2011 Le C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Following the widespread use of PCV7, dramatic reductions in the incidences of pneumococcal diseases caused by vaccine serotypes (VT) have been documented in many countries such as US [35-38], Germany [39], Norway [40], France [41,42], Canada [43], Australia [44], and other countries. On top of this, the use of PCV has led to the reduction in antibiotics-resistant strains of pneumococci and the rate of antibiotics prescribed [45-49]. PCV7 also has comparable effects in reducing the carriage rate of VT among the population [50,51]. PCV7 also resulted in reduction of most causes of pneumonia hospitalization in children less than 2 years of age in the US [35]. In AOM patients, a shift into and also the nontypeable Haemophilus influenzae as the emerging strains have been observed [52-54]. The herd immunity effect conferred by PCV7 appears to have indirectly benefited the non-vaccinated children and adults [43,44,55,56]. This is probably due to the indirect protective effects of PCV7 as a result of decreased VTs transmissions from the primary PCV age group [57,58]. However, the degree of effectiveness of PCV7-VT differs from 100% efficacy in serotype 9V (100%) and 23F (98%) to the lowest in 19F (87%) [51]. The efficacy of PCV7 also depends on several factors, including number of doses received, age of vaccination, proportion of vaccinated population, and geographical variations of serotypes [10,51,59].

The effect of PCV7 in reducing the VT was gradually dissolved by the concomitant increase in IPD due to non-vaccine serotypes (NVT). Findings from the post vaccination studies elsewhere underlined in particular the "serotype replacement" phenomenon [60,62] whereby significant rise in proportion of NVT were detected mainly with the multidrug resistant clone CC320 mainly emerged after the introduction of PCV7 [68,81-83]. In Europe, the increase in MDR pneumococci particularly the multidrug resistant (MDR) NVT strains as a result of selective pressures from the conjugate vaccine in parallel with the common antimicrobial agents used [36,38,64]. This indicates that the selected strains have not only escaped/avoided the immunity developed towards PCV7 but have also become more resistant.

Changes in the pneumococcal serotypes population can occur naturally due to the background fluctuation of pneumococcal serotypes [70]. In addition, the circulating genotypes may also change from time to time or due to the selective pressures from vaccines or antibiotic use. Isolates expressing the same serotype are usually, but not necessarily, have the same genotypes [71-73]. Molecular genotyping technique such as Multilocus sequence typing (MLST) has been increasingly used to investigate the sequence type (ST) of pneumococci based on the allelic variation of the seven housekeeping genes [73]. The collection of closely related strains with defined ST variances form the clonal complex (CC), which can be used to evaluate the relationship between the local clonal lineages to the international clones to deduce the pattern of global dissemination of the clones [73]. For instance, the global widespread of the Spain21-1 and France4-3 international clones have been documented in Europe and Asia [74-76]. Serotype that is associated with clone of higher antibiotic resistance tendency would in turn confer higher resistance to the associated serotype. For example, penicillin resistant or MDR clones of serotypes 14, 23F, 6B, and 9V have been reported in Spain since 1980s [77-79]. Prior to the introduction of PCV7 in the UK, significant reduction in ST306 which was associated with serotype 1 and a concomitant reduction in ST124 which was associated with serotype 14 have been reported [80]. In the postvaccination era, significant expansion of serotype 19A was mainly attributed to the clones CC199 and CC320 in the US [68,81-83]. CC199 represents the major clonal lineage even before PCV7 introduction but the multidrug resistant clone CC320 mainly emerged after the introduction of PCV7 [68,81-83]. In Europe, the increase in MDR serotype 19A was mainly associated with ST276 and ST320 [84].

In the developing world data on the pneumococcal disease burden have been very limited. The serotype epidemiology corresponding to the respective country is largely unavailable as well. The same situation is happening in many of the countries in Asia that represents the major barrier in estimating the pneumococcal disease burden in Asia. Its use is still mainly restricted to the private market on an individual basis to those who can afford the vaccination and this comprises a small percentage of the population. Hence, the actual effect could not be translated to benefit the whole community. This is largely due to the lack of information on disease burden and serotype distribution as well as the cost-effectiveness estimation with the widespread use of PCV’s [85,86]. Various efforts in introducing PCV7 to the developing world are currently underway but prior evaluations on the potential effectiveness of the vaccine must be collected [87-89]. A recent review by Lin et al. [90] focusing on pneumococcal disease burden among children in the Asia-Pacific region from 1999 - 2010, highest incidences of 100 - 200 cases per 100 000 children <1 or 2 years old and the preventable disease reach as high as 6 - 200 cases per 100 000 children. It was reported that the coverage of PCV7 is relatively low (45%) among the Asian countries [91,92]. Since PCV7 was initially designed to contain largely the IPD serotypes in the western countries and serotype distribution exhibit substantial geographical and temporal variations [59,93], the outcome might not be the same in Asia. For all the reasons mentioned above, there is an urgent need to revise into the most recent situation in serotypes distributions in Asia, which outlined the main objective for review article. Here we look extensively into the current five years trend of serotype epidemiology implicated in both invasive and noninvasive pneumococcal diseases in Asia. The associated ST and antibiotic susceptibility were also noted.

Methods

The MEDLINE (National Library of Medicine, National Institute of Health) database was used to identify relevant studies published between January 2006 and September 2011 on patients of any age group with invasive or noninvasive pneumococcal diseases. Isolates were collected from any site appropriate to the respective methodology. Several criteria were applied: (1) If the data involved consecutive sampling period from date prior to and the date defined above (e.g. year 2001 through 2008) and where the data is cumulative and not divisible by years, all data were included; If divisible, only data from the defined date is extracted for analysis (2) Not carriage isolates (3) Isolates are not subset of a particular pneumococci characteristics, such as serotypes of only levofloxacin-resistant pneumococcal isolates. The search was carried out in English and is limited to studies published in English. General search terms included: Streptococcus pneumoniae, serotype, and pneumococcal diseases, separated by binary operators as specific search term: “Afganistan”, “Armenia”, “Azerbaijan”, “Bahrain”, “Bangladesh”, “Bhutan”, “Brunei”, “Burma/Myanmar”, “Cambodia”, “China”, “Cyprus”, “East Timor”, “Georgia”, “Hong Kong”, “India”, “Indonesia”, “Iran”, “Iraq”, “Israel”, “Japan”, “Jordan”, “Kazakhstan”, “North Korea”, “South Korea”, “Kuwait”, “Kyrgyzstan”, “Laos”, “Lebanon”, “Macau”, “Malaysia”, “Maldives”, “Mongolia”, “Nepal”, “Oman”, “Pakistan”, “Papua New Guinea”, “Philippines”, “Qatar”, “Saudi Arabia”, “Singapore”, “Sri Lanka”, “Syria”, “Taiwan”, “Tajikistan”, “Thailand”, “Turkey”, “Turkmenistan”, “United Arab Emirates”, “Uzbekistan”, “Vietnam”, and “Yemen”. Relevant studies were also identified by hand searching of the reference list of the primary papers. In addition, occasional search of published articles and government/network surveillance databases were performed using Google search engine. Of all the countries listed only 17 had data
### Country/Territory

| Country/Territory | Study | Sampling perioda | no. of isolatesb | Sample typec | Age (years) |
|-------------------|-------|------------------|------------------|--------------|-------------|
| **East Asia**     |       |                  |                  |              |             |
| China             | Liu et al. 2008 [94] | 1/2005 – 12/2006 | 451              | both         | 1d – 4y     |
|                   | Chen et al. 2010 [95] | 2007            | 31               | non-invasive | <3          |
|                   | Xue et al. 2010 [96] | 2006 – 2008     | 171              | invasive     | <14         |
|                   | Yao et al. 2011 [97] | 2/2006 – 2/2008 | 338              | non-invasive (only one from invasive) | ≤5 |
|                   | Zhang et al. 2011 [98] | 3/2009 – 3/2010 | 91               | Both         | all         |
|                   | Zhou et al. 2011 [99] | 2010            | 140              | non-invasive | children    |
| Hong Kong         | Ip et al. 2007 [100] | 3/2005 – 3/2006 | 519              | non-invasive | 1m – 15y    |
|                   | Ho et al. 2011 [101] | 7/2005 – 12/2009 | 563             | invasive     | all         |
|                   | Hon et al. 2010 [102] | 1/2007 – 12/2009 | 12              | both         | children    |
|                   | Center for Health Protection Hong Kong, 2011 [103] | 9/2010 – 6/2011 | 160             | invasive     | all         |
| Taiwan            | Hsieh et al. 2008 [104] | 2003 – 12/2006 | 364             | invasive     | all         |
| Japan             | Suzuki et al. 2010 [105] | 2006 - 2007    | 323             | both         | all         |
|                   | Hotomi et al. 2008 [106] | 2/2006 – 6/2007 | 175             | non-invasive | 1m – 127m   |
|                   | Chiba et al. 2010 [107] | 8/2006 – 7/2007 | 492             | invasive     | all         |
|                   | Sakai et al. 2011 [108] | 1/2007 – 12/2009 | 115             | invasive     | ≤15         |
|                   | Oishi et al. 2011 [109] | 10/2007 – 12/2009 | 79             | both         | children    |
| South Korea       | Choi et al. 2008 [110] | 1991 - 2006     | 444             | both         | children    |
|                   | Song et al. 2009 [111] | 2007            | 94              | both         | all         |
|                   | Baek et al. 2011 [112] | 2008 - 2009     | 329             | both         | all         |
| Southeast Asia    | Hsu et al. 2009 [113] | 1/2000 – 12/2007 | 192             | invasive     | 14 - 96     |
|                   | Jefferies et al. 2011 [114] | 2001 - 2006 | 86            | invasive     | ≤16         |
| Malaysia          | Le et al. 2011 [115] | 3/1999 – 2/2007 (except 2001 and 2004) | 151 | both | all |
|                   | Yasin et al.2011 [116] | 1/2008 – 12/2009 | 433            | both         | all         |
| Thailand          | Srifeungfung et al. 2010 [117] | 1/2006 – 2/2009 | 214             | invasive     | all         |
|                   | Baggett et al. 2009 [118] | 5/2005 – 6/2007 | 74              | invasive     | all         |
| Laos              | Moore et al. 2010 [119] | 1/2003 – 4/2009 | 33              | invasive     | all         |
| South Asia        | Brooks et al. 2007 [120] | 4/2004 – 3/2006 | 34              | invasive     | <5          |
|                   | Saha et al. 2009 [121] | 5/2004 – 5/2007 | 137             | invasive     | <5          |
|                   | Arifeen et al. 2009 [122] | 7/2004 – 6/2007 | 26              | invasive     | <5          |
| Sri Lanka         | Ministry of Health Sri Lanka, 2008 [123] | 2006 - 2008 | 36              | invasive     | <5          |
| Nepal             | Williams et al. 2009 [124] | 4/2005 – 12/2006 | 17             | invasive     | 2m – 59m    |
|                   | Kelly et al. 2011 [125] | 4/2005 – 12/2006 | 34             | invasive     | ≤12         |
|                   | Shah et al. 2009 [126] | 11/2004 – 3/2007 | 28             | invasive     | 2m – 5y     |
|                   | Rijal et al. 2010 [127] | 11/2004 – 12/2008 | 47            | invasive     | 2m – 60m    |
| Pakistand         | Zaidi et al. 2009 [128] | 5/2005 – 4/2006 | 3              | invasive     | <5          |
| West Asia         | Al-Yaqoubi et al. 2011 [129] | 9/2002 – 12/2007 | 85            | both         | all         |
| Turkey            | Percin et al. 2010 [130] | 1/1998 – 7/2007 | 332             | invasive     | all         |
|                   | Ceyhan et al. 2010 [131] | 2005 – 2007     | 27              | invasive     | children    |
|                   | Ceyhan et al. 2011 [132] | 7/2008 – 2/2010 | 202             | invasive     | ≤18         |
| Palestine         | Kattan et al. 2011 [133] | 1/2001 – 4/2010 | 120             | invasive     | 1d – 11y    |
| Israel            | Somech et al. [134] | 1/1999 – 12/2008 | 5236           | non-invasive | <5          |

*aSpecific period of the sampled isolates included in the current analysis, might be only part of the original study conducted*

*bActual number of serotyped isolates included in the current analysis*

*cInvasive or noninvasive isolates*

*dPakistan is excluded from any of the analysis due to extremely low sample size (n=3)*

**Table 1:** Studies included in this review reporting pneumococcal serotypes data from Asian countries.
available for analysis in English and hence as such only these will be presented in this review. Table 1 summarizes the details of all the studies included in this review. The term National Immunization Program (NIP) was used to refer to the childhood or routine immunization program or equivalent throughout this review.

The combined percentage was calculated by summation of the number of isolates for the particular serotype from each study (as numerator) and divided by total number of isolates from each study (as denominator), adjusted to percentage (%). For regional and overall Asian estimations, respective data for countries/territories and regions were used directly and calculated using the same method. The serotype coverage of three licensed PCVs (PCV7, PCV10, and PCV13) was estimated via summation of the combined values (PCV7: 4, 6B, 9V, 14, 19F, 23F, 18C; PCV10: PCV7 + 1, 5, 7F; PCV13: PCV10 + 3, 6A, 19A) and includes the seven most common serotypes by country/territory, regions, and Asia in total. The serotypes distribution and predicted PCV’s efficacy based on our analysis are listed under Table 2.

Table 2: Current trend in predicted effectiveness of PCVs and prevailing serotypes in Asia.

| Country/Territory | Predominant Serotypes (%) | PCV coverage (%) |
|-------------------|---------------------------|------------------|
| East Asia         | 19F (19.9) 14 (11.1) 6B (10.7) 23F (10.4) 19A (6.9) 3 (6.4) 6A (3.8) | 7- 10- 13- |
| China*            | 19F (39.1) 19A (12.6) 14 (8.4) 23F (7.7) 6B (6.8) 15 (2.7) 6A (1.7) | 56.9 58.3 75.4 |
| Hong Kong*        | 19F (17.4) 6B (13.1) 3 (11.7) 19F (11.3) 23F (10.1) 4 (3.4) 19A (2.8) | 56.9 59.3 75.8 |
| Taiwan            | 19F (20.1) 23F (20.1) 6B (18.4) 14 (16.8) 3 (6.3) 15 (3.3) 23A (2.7) | 79.9 79.9 89.8 |
| Japan             | 6B (11.2) 3 (8.8) 19F (8.6) 14 (8.5) 23F (7.8) 12F/A (4.4) 6A (4.3) | 42.8 44.0 60.6 |
| South Korea       | 19F (20.3) 23F (14.1) 19A (12.0) 6A (9.0) 6B (8.7) 14 (6.9) 9V (5.0) | 57.3 58.2 83.0 |
| Southeast Asia    | 19F (14.4) 6B (11.7) 14 (11.2) 23F (7.6) 19A (6.0) 1 (4.4) 3 (3.9) | 49.9 56.5 69.7 |
| Singapore         | 14 (25.2) 6B (13.7) 3 (8.3) 19F (7.2) 8 (4.7) 23F (4.3) 19A (4.3) | 54.0 58.6 74.1 |
| Malaysia          | 19F (20.7) 6B (9.4) 19A (6.5) 23F (6.3) 14 (5.8) 1 (5.3) 6A (3.8) | 46.9 54.5 66.4 |
| Thailand          | 6B (16.0) 23F (13.2) 19F (10.1) 14 (9.0) 19A (8.9) 3 (4.5) 6A (2.5) | 54.2 57.6 72.6 |
| Laos              | 1 (18.2) 5 (12.1) 14 (9.1) 23F (9.1) 6 (9.1) 4 (6.1) | 30.3 83.6 68.7 |
| South Asia        | 1 (16.2) 2 (8.6) 5 (8.1) 14 (6.7) 12F/A (6.7) 23F (4.2) 19F (3.9) | 24.8 52.4 57.1 |
| Bangladesh        | 2 (12.2) 1 (11.7) 14 (8.6) 5 (7.1) 12F/A (7.1) 45 (6.1) 18C (4.6) | 24.4 47.2 53.8 |
| Sri Lanka         | 19F (22.2) 23F (16.7) 6B (13.9) 14 (11.1) 15B (8.3) 3 (5.6) 3 (5.6) | 63.9 83.9 69.4 |
| Nepal             | 1 (27.8) 5 (11.9) 12F/A (7.9) 2 (5.6) 7F (3.2) 4 (3.2) 19B/C, 16/36/47 (3.2) | 14.3 57.1 58.7 |
| Pakistan*         | 19F (66.7%) 1 (33.3%) | Not evaluated |
| West Asia         | 19F (14.3) 14 (13.4) 23F (9.2) 19A (9.0) 6B (7.2) 6A (5.3) 3 (4.0) | 50.8 58.5 76.8 |
| Oman              | 6B (11.8) 19F (11.8) 23F (11.8) 14 (7.1) 9A/L (7.1) 1 (5.9) 11A/D (4.7) | 45.9 57.6 65.9 |
| Turkey            | 1 (18.9) 19 (11.1) 19F (7.8) 3 (6.2) 14 (5.3) 4 (4.5) 16 (4.1) | 24.4 46.7 56.2 |
| Palestine         | 6A/B (14.2) 14 (13.3) 1 (11.7) 9V (9.2) 5 (7.5) 19F (6.7) 4 (5.0) | 55.0 77.5 85.0 |
| Israel            | 19F (15.2) 14 (14.4) 23F (10.1) 19A (10.0) 6B (7.4) 6A (5.9) 3 (3.8) | 53.6 59.3 79.0 |
| Asia              | 19F (16.2) 14 (12.1) 23F (9.4) 6B (8.9) 19A (7.7) 3 (4.8) 6A (4.4) | 52.4 58.1 75.0 |

*Serotypes in bold-face only denotes PCV7-VT; bold-face and italic denotes PCV10-specific VT in addition to PCV7; bold-face, italic, and underline denotes PCV13-specific VT in addition to PCV10
*Refer to mainland China only
*Hong Kong is one of the Special Administrative Territories of China and is analyzed separately
*Pakistan is excluded from any of the analysis due to extremely low sample size (n=3)
As the way in which the respective authors reporting serotypes/serogroups varied greatly among each other due to the serotyping method adopted, we have reorganized them into appropriate groupings to ease the analysis process and to standardize among all studies (e.g. serotype 9A and 9L become 9A/L). Hence the serotype reported here might differ slightly from the original paper but yet is accurately defined. Individual study with minor serotypes/groups categorized together as “other” was noted. Although these serotypes/groups might differ between the respective studies, these are mainly minor PCV-VT and the effect on the serotypes and PCVs calculations should be negligible.

**East Asia**

**China**

Many studies concerning pneumococcal surveillance have been reported throughout the years from China. The PCV7 was introduced in China in September 2008. Six studies [94-99] were included to describe the current situation of S. pneumoniae. Strikingly, serotype 19F alone accounted for approximately 40% of all isolates. Such pattern of major dominance by serotype 19F or any other single serotype was not observed anywhere in Asia and elsewhere in the world. The next most prevalent serotype is serotype 19A which differs vastly from serotype 19F by approximate three-fold in percentage. As a result, the predicted efficacy for PCV7 and PCV13 are relatively high (63.4% and 79.8%, respectively), mainly due to the abundance of serotype 19F and serotype 19A. The coverage by PCV10 does not differ very much from PCV7. Such dominance would be valuable from the public health perspective as more than half of the incidences among the Chinese can be prevented by just targeting two serotypes. Despite this, other common serotypes including 14, 23F, 6B, 15, and 6A also play important role in disease incidences as together, they accounted for about 80% of all cases in China. In terms of ranking order, this distribution is rather different (except 19F) from two previous studies describing serotypes detected from pediatric patients with respiratory infections [135,136]. Hence, the use of PCV13 is expected to produce the optimal coverage for the Chinese population in general. The remaining 20% is stratified fairly equally into more than 30 minor serotype/groups including nontypable strains. No major difference in serotype distribution and the PCV7 coverage was noted between children <2 and those 2 – 4 years old [94,96]. The serotypes 19F, 19A, 6B, and 23F have been reported by Zhang et al. [98] to be associated with the global predominant clones of ST271, ST320, ST90, and ST81 respectively. These clones were responsible for the highly-resistant isolates within the individual serotypes.

In addition, significant difference in serotype distributions due to geographical variations between different districts has been reported. Eastern and Southern Central China were reported to have more serotypes of PCV7 and thus PCV7 vaccination would be effective, but the coverage in Northern region was noted to be lower presumably due to lower presence of the vaccine types [97]. In another study, serotype 19A was commonly detected from northern regions but not southern and eastern regions [96]. Of note, the prevalence of serotype 19A in China had occurred even before the introduction of PCV7 [96].

As prescription is not compulsory, widespread use of antibiotics is common in China. Because of this, the rate of PNSP remained considerably high in China [97,98]. Although varied slightly between studies, the rate of PNSP is generally 58% - 88% [94,95,97,98] and these strains are likely to exhibit tolerability to other classes of antibiotics as well [98]. The high antibiotic selective pressure could have contributed to the selection of serotypes associated with resistance such as serotype 19A [94,97]. Serotype 19A has also been reported with high resistance against cefuroxime [97]. In addition, serotype 19A and serotype 5 were more invasive [94]. In contrast, serotype 19F was closely associated with PNSP (87.3%) but was rather noninvasive [94]. Of note, both the serotype 19F and 19A also exhibited higher (>50%) resistance against amoxicillin-clavulanic acid and ceftriaxone, and have greater tendency to become MDR strains [94] In China, the rate of MDR could reach up to as high as 90% and have been frequently reported [94-96].

**Hong Kong**

Since Hong Kong is considered one of two Special Administrative Territories (SAPs) of China, the serotype distribution will be evaluated separately. Of note, the prevalence of serotype 14, 6B, 3, 19F, and 23F, range from 17.4% to 10.1% and covers 63.6% of all isolates. PCV7 was introduced in Hong Kong in October 2005 and was incorporated under the NIP starting September 2009 [137]. PCV10 was made available in August 2009 and PCV13 in May 2010. The efficacy of PCV7 and PCV10 is predicted to be substantial (56.9% and 59.3% respectively) while for PCV13, 75.8% of the isolates were covered, mainly due to the inclusion of serotype 3. Of note, serotype 5 though only present in minority was reported to be highly resistant to erythromycin [101].

To evaluate the change in serotype epidemiology with the introduction but prior to routine immunization of PCV7, Ho et al. [101] conducted a multicenter study involving patients of all ages and covering >90% of isolates from the districts involved. Several important findings were noted where significant reduction was detected for three of the PCV7-VT 9V, 23F, and 14. The drop was greatest among children <5 years old (89.5% to 65.7%) while moderately in older adults ≥65 years old. Also, serotype distribution differed among age groups at which serotype 6B was the commonest among the children while serotype 3 was prevalent in adults. In addition, serotype 19A as well as 6A, 6B, 14, 19F, and 23F were frequently linked to dual resistance against penicillin and erythromycin. The rate of dual resistance had increase from 44.1% to 64.2% in children <5 years of age in the postvaccination era. Serotype 14 was the only serotype equally common across age groups. In contrast, the prevalence of PCV7-VNT 7F and 19A have seen significant increased but no change was noted with the PCV13-VNT over time. For this reason and also to provide additional protection against pneumococcal infections, a switch to the PCV13 to replace PCV7 is being considered [138].

Gradual increase in penicillin resistance strains since 1990s in Hong Kong was linked to the MDR clones, Spain23F-1 and Spain6B-2 [139,140]. In the mid 2000s, the incidence of PNSP was reported to be between 46 – 66% [141]. In recent years, the percentages of PNSP was still high (50% - 65%) and the nonsusceptibility to erythromycin and tetracycline were even higher (76% and 62% respectively) [100,102]. On the contrary, resistance to cefotaxime was lower (17% - 38%) while all strains were fully susceptible to vancomycin and fluoroquinolones (except ciprofloxacin at 2.3%). Expansion of the Spain ST320 clone had contributed to the rises of serotype 19A [101].

**Taiwan**

Since the data reported by Hsieh et al. [142] represent part of their earlier work in 2008 (64/68, except 4 new isolates), we evaluate the serotype distribution based solely on the initial study [104] to avoid redundancy. The four predominant serotypes in Taiwan, serotype 19F (20.1%), 23F (20.1%), 6B (18.4%), and 14 (16.8%) accounted for three quarters (75.3%) of the cases. Because of this, the efficacy of PCV7 is
exceptionally high (80%) among the Taiwanese population. PCV7
was licensed in Taiwan in October 2005. No additional protection
is conferred by PCV10 due to the absence of PCV10-specific VT in
Taiwan while PCV13 gave an additional 10% in coverage. Thus, great
majority of the pneumococcal disease incidences among the Taiwanese
population could have been prevented by the use of PCVs. Moreover,
the efficacies of all three PCVs are highest in Taiwan as compared to
other Asian countries.

Serotype 14, 23F, and 6B were reported to be associated with
pneumonia, bacteremia, and meningitis, respectively [142]. A number of
serotypes which were linked to the internationally-disseminated
clones, namely England serotype 14 ST9, Spain 23F ST81, Spain 6B
ST95, Colombia 23F ST33, Taiwan 19F ST236, and Taiwan 23F ST242
were widespread in Taiwan and responsible for approximate half of
all invasive isolates [142]. The prevalence of resistant serotype 19F in
Taiwanese children was attributed to the expansion of Taiwan 19F
ST236 [142]. Beside the international clones, the penicillin-resistance
clones ST576, ST46, ST76, and ST2889 were recently identified in
Taiwan and believe to be the main invasive clones prevailing among
the children [142]. Higher invasive tendency of certain serotypes have
also been reported [143]. In particular, serotype 14 was well recognized
for its invasiveness and IPD causing ability [144-147].

The problems of penicillin- and macrolide-resistant S. pneumoniae
have long been recognized in Taiwan [144,145,148]. High resistance
to erythromycin and penicillin were constantly reported [104] and
cephalosporin resistance has also been reported since 2005 [149]. This
pattern of resistance was related to geographical distribution of the
isolates as well [104]. On the contrary, susceptibility to coamoxiclav,
vancomycin, and fluoroquinolones (lovoxacin, moxifloxacin,
gemifloxacin) were high.

Japan

Japan has very well-established coordinated surveillance network.
This is seen with a number of recent studies involving multicenter,
single prefecture [105], large multicenter-multiprefecture [108], as well
as two nationwide surveillances [106,107]. Of course, separate single-
centered study that also provided valuable finding [109]. The overall
predominant serotypes based on these five recent studies are as follows:
serotype 6B, 3, 19F, 14, 23F, 12F/A, and 6A. The predicted PCV7
effectiveness among the Japanese would be 42.8%, 55.2%, and 71.7%.
If serogroups 6 and 19 which were nondifferentiated by Suzuki et al.
[105] were included, further 11.2% additional coverage is expected
for each PCV. In February 2010, PCV7 was available in Japan and has
become the routine immunization recently in 2011. We do not
observe serotype 19A in Japan to be as common as in other East Asian
countries. However, two individual studies [107,109] had pointed out
the relatively high incidence of serotype 19A (approximate 6 -
13%) and this rate was higher than the Western countries during the
prevaccination era [43,55,56,150]. Hence, this warrants the continued
monitoring of the serotype epidemiology in Japan.

Sepsis was the more common cause of IPD among the Japanese
(46.2%), followed by pneumonia (31.5%) and meningitis (17.5%) [107].
Serotypes 19F, 14, and 6A were the predominant serotypes in pediatric
community-acquired pneumonia [151]. Remarkably, great majority
(92%) of pediatric IPD cases were children aged ≤4 years of age [107].
Meningitis was most frequent during infancy period (<12 months)
and it has been predicted that PCV7 and PCV13 shall protect 70.6%
and 82.4% of the cases [108]. In addition, the four most predominant
serotypes from our analysis above (except serotype 3) also represent the
common serotypes responsible for pediatric meningitis as reported by
Sakai et al. [108]. On the other hand, two third of strains isolated from
children with AOM aged ≤2 years were PNSP.

The higher penicillin tolerability in serotype 19F and 23F might be
the factor contributed to the higher penicillin resistance among AOM
isolates obtained from the younger children [106]. Similar finding was
reported in Niigata prefecture at which the PNPS rates in serotype 19F
and 23F were as high as 92.9% and 84.6% respectively [109]. Other
important PNSP serotypes noted were 6B (73.3%) and 14 (100%, n=4
only), respectively [109]. Among the PNSP, serotype 19F has the largest
proportion of PRSP (61.5%) as compared to 23F (18.2%) and 6B (9.1%).
In contrast, the prevailing PSSP serotypes were 19A (n=6/10) and
33F (n=2/2, low sample size) [109]. This suggests the clear difference in
serotype distribution between PSSP and PRSP serotypes. However, this
does depends on the study methodology adopted as Suzuki et al. [105]
had observed no significant association between PNSP with specific
serogroups. Hence, the relationship between these two determinants
remained elusive.

Interestingly, although penicillin-resistance has observed gradual
increase since 1998 in Tohoku, the incidences then fell slightly recently
following the peak in 2004 [105]. The underlying PNSP serogroups 19
and 23 persist steadily over years, but serogroups 6 and 14 becoming
less common since 2002. Close association among serotypes and STs
were observed [108]. The high heterogeneity of STs (especially among
the dominant serogroups/sttypes) as well as the proportion of novel STs
in Japan were also reported by Jefferies et al. in Singapore [114]. High
homogeneity in DNA restriction patterns were noted among strains of
same resistance genotype, thus strongly indicates that the widespread
were originated from a few parent strains to distant areas [107].

South Korea

Similar to China, serotype 19F is the most common (20.3%) in
South Korea while, serotype 23F ranked second with 6% lower in
percentage. Other serotypes include 19A, 6A, 6B, 14 and 9V and these
are the seven most common serotypes which cover 76% of the isolates.
PCV7 and PCV10 are expected to provide coverage to more than
half (57% - 58%) of the isolates. On the other hand, PCV13 confers
significant enhancement by 25% in addition to PCV7 and PCV10
which is largely due to the inclusion of serotype 19A and 6A.

Most of the children from urban areas have received PCV7
vaccination since the introduction of PCV7 in November 2003 [111].
Significant reduction in PCV7-VT such as serotype 19F and 23F and
an increase in PCV7-NVT have been well-documented in South Korea
[110-112]. However, no reduction in prevalence of serotype 14 was
observed and this serotype was mainly related to the presence of the
CC554 clonal complex [112]. Although the actual reasons were not
clearly stated, the lower effectiveness of PCV7 against serotype 14 led
to the postulation of the possible existence of undiscovered serotype
14 subtypes [112]. This is similar to the recent discovery of serotype 6
subtypes (6C and 6D) that responded differently to the PCV7 due to
cross-reactivity from VT 6B.

Serotype 19F showed diverse genotypic heterogeneity whereby as
high as 18 STs were found to associate with this serotype and ST271
represented the dominant clone [110,111]. In contrast, increasing
prevalence of the PCV7-NVT serotype 19A postintroduction was
essentially due to the underlying single clonal expansion of ST320
[110,111]. In fact, all recent serotype 19A isolates were ST320 based on
a study performed by Song et al. [111]. Furthermore, prevalence
expansion of serotype 19A due to ST320 has been reported [110]. Interestingly, ST320 has also been detected in serotype 19F and the author hypothesized that ST320 might have been originated from the serotype 19F dominant clones ST271 or ST236 [110]. These clones are already in existence in South Korea for the past two decades ago [152]. Unlike serotype 19F, genotypes of serotype 19A were much less diverse [110]. In addition, the inherent MDR property of ST320 probably had conferred additional survival advantage to serotype 19A against antibiotic selective pressure rendering the continued expansion of this serotype even with widespread antibiotics usage in South Korea [110]. This has also contributed to the domination by ST320 over other serotype 19A genotypes such as ST1374 which were less resistant to beta-lactam antibiotics [110].

On the other hand, the increase in serotype 6A has also been noted and was related to ST81 genotype or its single or double locus variants [112]. Interestingly, this serotype 6A-ST81 association was only reported in and widely distributed in South Korea [111,112]. The same was observed with serotype 6B-ST282 and this genotype has become the dominant clone of serotype 6B [112]. Unlike serotypes 19F and 19A, no common ST was found between 6B and 6A.

**Southeast Asia**

**Singapore**

PCV7 was introduced in Singapore in October 2005 and later be incorporated under the NIP in November 2009 [153] thus the data types 14, 6B, 3, 19F, 8, 23F, and 19A, which account for 67.7% of IPD cases. The proportion of the most dominant serotype 14 is about two-fold higher than the second serotype 6B. The serotypes distributions observed in these studies [113,114] were comparable to previous study by Chong et al. [154]. No significant fluctuation with regard to the serotypes associated with PCV7 and PIPV23 was observed throughout the years [113], partially due to the fact that PCV7 has not been incorporated under the Singapore NIP.

Recently, Jefferies et al. [114] reported data on clonal relationship among the IPD isolates using MLST. The predominant STs in decreasing order were: ST9 (12.8%), ST156 (7.0%), ST236 and ST90 (5.8% each). Two of the predominant serotypes, 14 and 6B displayed widest genotypic heterogeneity with 15 and 14 STs respectively. In addition, studies conducted earlier by the same group in UK [80,155] also showed high number of serotype 14 as well as the high heterogeneity (12 STs) of this serotype. Such occurrence can be attributed to, in part, the genomic dynamicity which facilitates the adaption of the strain against drug selective pressure [156]. High percentage (32%) of the reported genotypes were indeed novel STs, suggesting potential undiscovered STs in Singapore as well as the SEA region [114].

**Thailand**

Two recent studies have reported serotype distributions in Thailand: one covering the heavily-populated urban area in central Bangkok (Bangkok, Nakorn Prathom, and Nonthaburi) [117] and another covering two rural areas (Nakhon Phanom and Sa Kaeo bordering Laos and Cambodia, respectively) [118]. The most common serotypes based on data from these two studies are 6B (16.0%), 23F (13.2%), 19F (10.1%), 14 (9.0%), and 19A (6.9%), 3 (4.5%), and 6A (3.5%), responsible for 63.2% of all. Overall, the coverage for PCV7 and PCV10 are around 56% while PCV13 has better coverage at 72.6%. It was reported PCV7 covered 70.3% of the invasive isolates from Thai children <5 years of age [117], with serotype 6B and 23F highest at 21.9% each, 14 (17.1%), 19F (6.2%), and 4 and 9V (1.6% each). Serotype 19A (7.2%) was the highest non-VT strains, followed by 6A (3.6%).

The distribution of VT remained fairly stable although with the introduction of PCV7 since June 2006, probably due to the low vaccination rate among the population. The low coverage rate of PCV7 especially among the low- and middle-income families is mainly attributed to the high cost of PCV7 vaccination (~122 USD/ dose) [5] and competing interest from other vaccines under the NIP [118]. The newer generations of PCV (PCV10 and PCV13) are predicted to confer greater coverage (84% and 95% respectively).

The penicillin- and ciprofloxacin-susceptibility were high in Thailand, but at the same time the resistance to cotrimoxazole (55%) was also high in Thailand [117,118]. Prevalence of PNSP has been steadily increasing over the years from 63% in 1997-1998 [158] to 69% seven years later [159]. The rate climbed further to as high as 73.8% among non-invasive isolates in young children recently [117]. Fortunately, most antibiotic-nonsusceptible strains belonged to the PCV7-VT [118] and approximately 83% and 100% of PNSP and cefotaxime-nonsusceptible strains were covered under the PCV7 formulations [117]. From the same study, the author also expressed the concern on the detection of cefotaxime-nonsusceptible strains because cefotaxime has been the main treatment choice for pneumococcal meningitis in Thailand.
Laos

Study on pneumococcal disease burden in Laos is extremely limited. The first study was only reported in year 2006 by Phetsouvanh et al. [160] and recently by Moore et al. [119] in year 2010, both based in Vientiane, the capital city of Laos. Only data from the latter study was discussed in this review as the sampling period of the former one was during year 2000 – 2004. The most prevalent circulating serotypes in Laos are 1 (18.2%), 5 (12.1%), 14, 23F and 6 (9.1% each), and 4 (6.1%). All other detectable serotypes/groups had only one isolate (3.0%). Although serotype 1 is generally recognized as the “outbreak” serotype [161-163], the author found no linkage between serotype 1 and any disease outbreak among the patients examined [119]. Interestingly, serotype 19F that is highly prevalent in other Asian countries especially Malaysia, Singapore, and Thailand, as mentioned earlier in this review was not a frequent serotype in Laos. The predicted PCV7 coverage (assuming 6A/B/C to be PCV7-VT) is 39.4%. However it is predicted that the coverage rate increase dramatically to 63.6% if PCV10 is used and a further 3% if PCV13 is used. Based on these data, PCV7 vaccination in Laos might be the two (oral vaccine candidates) to be considered. However, due to the low sample size (n=33), continued monitoring of serotype distribution in Laos is urgently needed to provide comprehensive data. Apart from this, the isolates exhibit full susceptibility to ceftriaxone and rifampicin while 61% of the isolates were resistant to cotrimoxazole.

South Asia

Bangladesh

Three recent studies [120-122] have conducted extensive population-based studies on pneumococcal serotype distribution involving countrywide coordinated surveillance of both urban and suburban areas in Bangladesh. We noted that the above mentioned surveillances have in common investigated the IPD burden among young children <5 years of age. Since seeking healthcare services in the course of infections is rather uncommon, thus active population-based surveillance is important and would better reflect accurately the pneumococcal disease burden in Bangladesh [122]. The estimated overall incidences of IPD is 86 cases per 100 000 child-years of observation [122]. Among those <5 years of age, respiratory tract infections is the main manifestation and more than 90% of total pneumococcal isolates were obtained from children ≤24 months old [121]. Of note, since all three studies reviewed here had not involve any older age groups (≥5 years old), thus the data is skewed towards the young children.

The current prevailing serotypes (in decreasing order) are as follows: serotype 2 (12.2%), 1 (11.7%), 14 (8.6%), 5 and 12 F/A (7.1% each), 45 (6.1%), and 18C (4.6%). All other minor serotypes/groups were sparsely distributed at <4.1%. From our analyzed data, we express a concern over the efficacy of PCV among the Bangladesh populations. As all recent studies examined specifically the young children, which are also the PCV-targeted group, only two (serotype 14 and 18C) of the PCV7-VT are found among the seven most prevalent serotypes but merely at the rate of 13.2% in total. Thus, the low efficacy of PCV7 among Bangladeshi children (24.4%) is expected. Compared to all other Asian countries, the coverage of PCV7 is more than two-fold than in Bangladesh (except Nepal, Laos, and Turkey). Even with PCV13, additional of 29.4% to 53.8% coverage rate is still comparatively low.

The more striking finding from the analysis is that a number of serotypes 2, 45, and 38 are responsible for 20.8% of the cases. The highly abundant serotype 2 as well as 45 is rather unique to Bangladesh as reports of these serotypes from other Asia countries is extremely rare which usually present as minor strains (not more than 5% rate). Serotype 2 has almost never been detected from the developed countries [92]. In addition, this serotype has undergone stable expansion in Bangladesh since 1992 until now [121,164,165]. Importantly, it should be noted that this expansion of serotype 2 is not due to “serotype replacement” as PCV usage is still low in Bangladesh [122]. Although it has been predicted that widespread use of PCVs can prevent >1 million pediatric pneumonia cases in Bangladesh [120], the low coverage rate of PCVs shall mean that pneumococcal infections might not be efficiently controlled by PCVs among the Bangladesh population. In comparison, the coverage for pneumonia and bacteremia by PCV10 and PCV13 is better than meningitis serotypes [121]. The serotype distribution in Bangladesh has observed noticeable changes over time. Serotypes 1, 2, and 5 are emerging while 12F and 15B are becoming less common [121].

In contrast to China, South Korea, and Taiwan, and others, in Bangladesh, susceptibility of S. pneumoniae to penicillin is high (>84%), as well as to chloramphenicol (>85%), and ciprofloxacin (>96%, except for the 76% rate reported by Brooks et al. [120]) [120-122]. No significant change in penicillin and chloramphenicol susceptibility was observed over the past decade [164,166,167]. In contrast, susceptibility to cotrimoxazole is low (<28%) which was demonstrated by a previous study [164]. This was reasoned to be due to widespread use of cotrimoxazole by community healthcare workers [121]. Nevertheless, use of cotrimoxazole as the main therapeutic agent is still in practice even though amoxicillin has been proposed to be the better drug with superior efficacy [166,168]. This is partly due to the arguable in vitro susceptibility profile and the treatment outcomes [169].

Sri Lanka

Sri Lanka is one of the members of the South Asian Pneumococcal Surveillance (SAPNA) network. The nascent pneumococcal replacement project in Sri Lanka is managed by the Epidemiology Unit of Ministry of Health Care and Nutrition of Sri Lanka [123]. Encouraging efforts to control significant morbidity and mortality was undertaken by the Sri Lankan policymakers. Although PCV7 is available, low vaccine coverage rate among the population is expected considering the high cost of the dose. Focus is now on pneumococcal vaccination but we need to note that the NIP (termed Expanded Programme of Immunization, EPI) in Sri Lanka is self-funded, thus ample data on pneumococcal disease burden and vaccine coverage must first be collected so as to provide adequate assistance towards policy and decision-making processes. Hence, joining the SAPNA in 2004 greatly reflected the desire of the Sri Lankan government to take a step further to improve the healthcare of the population.

The serotype prevalence was estimated based on the latest report (with additional isolates) by the Epidemiological Bulletin of Sri Lanka in 2008 [123] as data published by Batuwantudawe et al. [170] constituted part of the work. Important findings underlined in both reports are discussed. Four of the most prevalent serotypes are all included under the PCV7, giving the predicted efficacy among the children <5 years old (subject population of the study) to be 63.9%. The distributions order are: serotype 19F (22.2%), 23F (16.7%), 6B (13.9%), and 14 (11.1%). Thus, the PCV7 and newer PCVs would be highly effective for Sri Lanka. Together with serotype 15B (8.3%), 3 and 38 (5.6% each), these seven serotypes accounted for the great majority (83.3%) of the isolates detected. However, the sample size
(n=36) is still small and continue surveillance is needed. Similar to Bangladesh, the pneumococcal isolates exhibited high tolerance to cotrimoxazole (69.7%) and high susceptibility to chloramphenicol (72.7%), but differ significantly with regard to the rates of penicillin (90.9%) and erythromycin (66.7%) nonsusceptibility. The overly high resistance to penicillin is of concern and the situation is closely similar to countries from the East Asia. Serotypes 19F and 23F were closely associated with penicillin-resistance which has contributed to the high PNSP rate observed [170]. However, the antimicrobial susceptibility of the isolates has not been analyzed for correlation with regard to the serotypes.

Nepal

Nepal is one of several countries in the world with a high poverty rate. It was estimated that one over three of the population are living below the poverty line [171]. Nepal is among 72 countries qualified for financial support from the Global Alliance for Vaccines and Immunization (GAVI) alliance. The data was analyzed based on surveillance studies by four research groups, two based in Kanti hospital [126,127] and two based in Patan hospital [124,125]. Both hospitals are situated within Kathmandu of Nepal and are the only two hospitals providing pediatric health care services. The most common serotypes are serotypes 1 (27.8%), 5 (11.9%), 12F/A (7.9%), 2 (5.6%), 7F, 4, 19B/C and 16/36/47 (3.2% each). None of the PCV7-VT appears as single dominant group, which gives a low (14.3%) predicted efficacy for PCV7 and also the lowest among all other Asian countries. This coverage is much lower than Bangladesh. Since both countries resided within the same region, it could possibly be due to geographical or demographical relationships between them leading to such observation. Despite this, a drastic increase in 42.8% coverage of PCV10 which is higher than Bangladesh is estimated with the inclusion of serotype 1, 5, and 7F. PCV13 has only minimal (1.6%) additional coverage due to serotype 19A alone. In this case, at least PCV10 or PCV13 should be the vaccine to be considered by the Nepal local policymaker since PCV7 is not expected to give sufficient protection to the population. Of note, pre-hospital antibiotic use could affect the isolation of pneumococci from the specimens which resulted in underestimation of actual pneumococcal incidences in Nepal [124-127]. In addition, the authors have noted the high incidences of pneumococcal diseases among young children in Nepal [172].

All except one [125] study documented the antimicrobial susceptibility of S. pneumoniae in Nepal. The only antibiotic that showed considerable resistance is cotrimoxazole, which exhibit >48% reduced susceptibility. This overwhelming resistance was also reported in Bangladesh and Sri Lanka, largely due to the low cost, easy availability, and frequent prescription of cotrimoxazole by the attending doctor in this region [124,126,127]. Hence cotrimoxazole exhibited significantly higher resistance as compared to other class of antibiotics. Other antibiotics including penicillin, chloramphenicol, erythromycin, and cefotaxime remained highly effective against the strains tested, with susceptibility of more than 95%, 89%, 92%, and 96% respectively [124,126,127] due to infrequent use of these drugs in Nepal [126]. Low incidence of penicillin-resistance has also been reported in central Europe [173,174].

Pakistan

Due to the extremely low pneumococcal sample (3/15 available for serotyping) in the only Pakistani study by Zaidi et al. [128], the data could not accurately represent the IPD serotypes circulating in the population and thus was not included in our analysis to avoid extreme bias. Nevertheless, several important findings outlined were noted. The detection of two serotype 19F and one serotype 1 out of the three isolates might indicates that these serotypes are more frequently detected among the population. Pneumonia is responsible for the more serious public health problem as compared to menigitis in Pakistan. More than 1 million cases and approximate 135 600 deaths in Pakistan were attributed to pneumonia annually. These two serotypes are included under the PCV7 (19F) and PCV10 (19F and 1) formulations. Similar to Nepal, Pakistan is one of the countries eligible for GAVI financial support. Although the current data is insufficient to evaluate the PCV efficacy, the author estimated that assuming PCV7 is incorporated under NIP with 50% protection efficacy against VT detected from the meningitis cases, the use of PCV7 will not only save the young children life but at the same time provide financial burden relief to the individual and the government as a whole.

West Asia

Oman

The coverage of PCV7 among the Arabian Peninsula and Egypt was estimated to be 49% - 83% [175]. Data based on the only available study by Al-Yaqoubi et al. [129] showed that about 46% of the diseases isolates in Oman was covered by PCV7. The impact of PCV13 is of little additional effect (3.1%) as compared to PCV7. However, high coverage (62.6%) of PNSP by PCV7 represents an additional benefit for reducing the incidence of penicillin-resistance in Oman. A total of 60.0% of the pneumococci obtained from various specimens of patients of all ages were serotype 6B (11.8%), 19F (11.8%), 23F (11.8), 14 (7.1%), 9A/L (7.1%), 1 (5.9%), and 11A/D (4.7%).

Turkey

S. pneumoniae was recognized as the predominant bacterial pathogen implicated in community-acquired sepsis in central region of Turkey where the mortality rate in adults could reach up to 50% [176]. About one third of bacterial menigitis in Turkish children was attributed to pneumococci [177]. High percentage of Turkish invasive strains were obtained from CSF specimen and these menigitis isolates were significantly associated with penicillin resistance in children but not adults (p < 0.05) [130]. No other relationship between serotypes and invasive sites was found. However such studies were few and need further substantiation.

The PCV7 was introduced into the Turkish NIP in November 2008. Of the three studies included [130-132], one involved data reported during and after the routine immunization [132]. The estimation based on specific serotypes showed that PCV7, PCV10, and PCV13 coverage are relatively low among Turkish with 24.4%, 46.7%, and 56.2% respectively. However, if we included the percentages of the serogroups 19, 18, 23, 6, and 7 reported by Percin et al. [130] and one serogroup 6 isolate by Ceyhan et al. [132] into the estimations, the coverage will be enhanced by more than 20% to 45.5%, 70.6%, and 80.0% respectively. The superior coverage by PCV10 and PCV13 over PCV7 are clearly evident despite the slightly overrepresented values due to the non differentiated serogroups. The comparatively high coverage by PCV10 and PCV13 are mainly attributed to the high prevalence of serotype 1 (18.9%), which is also the predominated serotype in Turkey. Other common serotypes detected were serotypes/groups 19 (11.1%), serotype 19F (7.8%), 3 (6.2%), 14 (5.3%), 4 (4.5%), and 18 (4.1%). Compared to a previous study by Firat et al. [178] which detected a large proportion of serotypes/groups 23, 19, and 14, serogroup 14 had become less common while serogroup 23 was not even a common serogroup.
However, the study focused only on pneumococcal meningitis isolates hence the differences might also be due to the type of isolates sourced from patients. The NTN serogroups 15 and 20 are responsible for 10% of invasive diseases among children <3 years old [130].

Ceyhan et al. [131] estimated that PCVs are predicted to be highly effective among children <2 years old, covering all cases (100%) with the use PCV13 but the effect was lower among the older aged children. Serotypes/groups 6, 14, 19, and 23 were also found to be associated with PNSP strains [176,178-180]. Of these serogroup 19 was frequently detected from children ≤2 years old but the proportion gradually reduced with increasing ages up to ≤18 years old with the majority (66.2%) of PNSP being detected in younger children [132]. It was surprising that the rate of penicillin resistance remained fairly low (6% - 13%) despite the easy availability even without prescription in Turkey [130,181]. The rising incidence of PNSP in Turkey had been reported previously [182]. In a separate study by Telli et al. [181], serogroup 19 was the largest group detected among macrolide-resistant S. pneumoniae. In addition, a significant proportion (35.3%) of the MDR strains showing resistance to penicillin and/or cotrimoxazole belonged to serogroup 19 [130]. Based on the experience in US and Europe, decrease of PNSP as well as other antibiotic-resistant strains in Turkey is expected with the routine immunization [49,183]. Whilst resistance to cefotaxime, chloramphenicol, vancomycin, tetracycline, and fluoroquinolones (levofloxacin) were low (<5%), macrolide (azithromycin, erythromycin) and cotrimoxazole resistances are high (>35%) [130,181]. A number of studies had similarly found ermB to be the dominant macrolide-resistant genotype [181,184,185] but no clonal dissemination of the macrolide-resistance strains were detected [181].

Palestine
Serotypes 6A/B (14.2%, not differentiated), 14 (13.3%), 1 (11.7%), 9V (9.2%), 5 (7.5%), 19F (6.7%), and 4 (5.0%) are among the common serotypes, accounting for 67.5% of all isolates reported in Palestine. Fortunately, five of these dominant serotypes are covered by PCV7 (assuming 6A/B as VT) and all seven are covered by PCV10. Hence, this reflects the potential high efficacy of PCVs among the Palestinians. PCV7 coverage is estimated to be 55.0% (including serogroup 18) while PCV10 and PCV13 cover 77.5% and 85.0% of the isolates, respectively. The prevalence was predicted based on patients ≤11 years old suspected with sepsis or endocarditis, but no meningitis or pneumonia cases were included due to the rare occurrence of these infections in Palestine [133]. Overall, all were susceptible to vancomycin and almost all (98.3%) of the isolates were susceptible to penicillin and oloxacain [133]. In contrast, susceptibility to erythromycin and cotrimoxazole were lower at 68.3% and 38.3% respectively and serotype 14 was indeed responsible for majority (75%) of the less susceptible isolates from these two classes of antibiotics. This is further supported by the fact that 53.3% of serotype 14 isolates were resistant to two or more antibiotics [133].

Israel
A study performed by Somech et al. [134] investigated into the serotypes causing pediatric AOM in Southern Israel. Although the isolates under studied were from noninvasive middle ear fluid and does not represent the more invasive serotypes, the data was used to reflect partly the current overall serotype distribution in Israel. Based on the data, the most common serotypes, serotype 19F (15.2%), 14 (14.4%), 23F (10.1%), 19A (10.0%), 6B (7.4%), 6A (5.9%), and 3 (3.8) accounted for two thirds of the isolates. Apart from the PCV7-VT, the PCV13 specific serotypes were also listed among the major serotypes. PCV7 has been incorporated under NIP since July 2009. The predicted PCV7 and PCV10 effectiveness among the Israelis are 53.6% and 59.3% respectively and the proportion is further enhanced by approximately 20% with PCV13, mainly due to the inclusion of three prevailing PCV13-VT. Children under 2 years of age accounted for the great majority (90%) of AOM patients among all children aged 5 and less [134]. The author noted the ethnic-dependent differences in serotype distribution, where serotype 14 was common among the Jewish children but serotype 19F was the dominant one among Bedouin children [134]. Thus, the predicted PCV7’s coverage also differed between them with Bedouin children having 10% lower protection than the Jewish children. On the other hand, reduction in cotrimoxazole nonsusceptibility over years was accompanied with the concurrent increase in macrolide-resistance as well as the proportions of MDR strains [134]. This is speculated to be due, in part, to the decreased usage of cotrimoxazole in southern Israel. Similar findings have been reported by previous studies [186-188], however, no significant changes over the years have been observed with penicillin nonsusceptibility. Despite this, the considerably high proportion of macrolide-resistance and MDR strains covered by PCV13 represent a strong supporting factor for the potential shift to PCV13 in the future.

Discussion
All the data reviewed here showed the latest five year trend of the prevailing serotypes causing various invasive and noninvasive pneumococcal diseases in Asia. Unlike the US and many European countries, most of the countries in Asia being reviewed here, have PCV7 introduced but not yet into the NIP. Hence the data are likely to reflect the baseline serotype distribution with minimal changes due to the vaccine’s selective pressure on serotypes.

Although PCV7 is introduced in Asia, only a small number of countries have officially incorporated the vaccine into the NIP (based on data available only for 17 countries). The overall PCV7, PCV10, and PCV13 coverage predicted are 52.4%, 58.1%, and 75.0%, respectively. If we include the nondifferentiated serogroups, the coverage increases slightly to 54.8%, 60.6%, and 77.5% respectively. The addition of serotypes 3, 19A, and 6A into the PCV13 formulation are expected to confer higher protection with the number of serotypes included, but this specific formulation is proven to be of exceptional performance at which as much as 17% increase in coverage as compared to PCV10 has been observed. On the other hand, PCV10 has comparatively little advantages effect over PCV7 with only a 5.7% increase in coverage. In Asia, about half (54.2%) of the disease burden is said to be due to serotypes 19F, 14, 23F, 6B, and 19A. This is followed by serotypes 3 and 6A which further covers 9.2% of the incidences. Fortunately, all these prevailing serotypes are formulated in the currently available PCVs, mainly in the PCV7 and PCV13. Although large numbers of diverse serogroups/groups were detected, only three serotypes predominate in Asia. Serotype 19F represents the dominant serotype in majority (7 out of 16) of countries/territories which included China, Taiwan, South Korea, Malaysia, Sri Lanka, Pakistan, and Israel. On the other hand, serotype 1 is the most prevalent in three countries, Laos, Nepal, and Turkey. This serotype is commonly found in developing countries [10,92] and together with serotype 5, they are widely recognized as “developing country serotypes”. The special features with serotype 1 are that it is invasive and is frequently associated with outbreaks [161-163]. However, there is no evidence of outbreak reported in any of the studies reviewed here and this therefore needs further substantiation with its relatedness to outbreaks. It is possible that serotype 1 has
become a persistent serotype in the populations like other serotypes but this requires further supporting studies. Apart from this, serotype 6B is more prevalent in Japan and Thailand (serotype 6A/B in Palestine) while serotype 14 is more prevalent in Singapore and Hong Kong. Notably, Bangladesh is the only country with high prevalence of serotype 2.

Since the serotype distributions displayed remarkable difference by geographical location [96,97], it is important to examine this from the perspective of regions where the particular country is located in. In the East Asia and SEA regions, it is interesting to note that both have almost same serotypes prevalence order for serotype 19F, 14, and 6B, 23F, and 19A, differing only with the ranking order of serotype 14. Moreover, a similar pattern is observed in West Asia ranking of serotypes 23F, 19A, and 6B. In contrast, the serotype distribution is quite different in the South Asia region. As observed apart from serotype 1, other prevalent serotypes such as 2, 5, and 12F/A are rare in SEA, East Asia (only serotype 12F/A at 4.4% in Japan), and West Asia (only serotype 5 at 7.5% in Palestine). For serotype 1 which is the most prevalent serotype in South Asia, it is less frequently detected elsewhere in West Asia and SEA but not in East Asia. However some exceptions have been observed as that in the single study reported by Moore et al. [119], where the serotype distribution in Laos appeared to resemble that of South Asia. A similar situation is also observed with the pattern of serotype distribution in Sri Lanka which differed greatly among other South Asian countries, and the four most prevalent serotypes (19F, 23F, 6B, 14) closely resembling those from all other three regions. The overall effectiveness of the three PCVs by regions in highest to lowest order are East Asia > West Asia > SEA > South Asia.

We also noted the presence of some NVT belonged to the common serotypes in the respective regions. Serotype 15 has been reported in China and Taiwan. Despite being defined as VRT, serotype 23A is rather common in Taiwan as well. Together, Taiwan has a greater number of NVT than any other countries from the same region. In addition, serotype 12F/A has been reported in Japan as well. Towards the south, countries in SEA have similar serotype distribution. Singapore is the only country in SEA commonly reporting NVT, specifically serotype 8. Also in West Asia, serotype 9A/L and 11A/D (as 9A and 11A in study conducted by Mubarak et al.) is only identified in Oman as one of the common serotypes, but none elsewhere in Asia. On the other hand, serotype 5 is unique to Palestine. In South Asia, a number of NVT are found to be common with serotype 2 being reported in Nepal and Bangladesh. Most strikingly, this serotype represent the dominant serotype in Bangladesh as well as serotypes 12F/A and 45. Altogether, these three NVT occupy a quarter of all incidences in Bangladesh. Because of this, the estimated PCVs coverage among the Bangladeshi population became substantially low. Poor PCV7 coverage has been reported in Malawi [189]. In Asia the lowest coverage of PCV7 is seen in Nepal. One of the reasons is because Nepal is predominated by NVT, namely 12F/A, 2, 19B/C, and 16/36/47 which is responsible for about 20% of pneumococcal infections in the Nepalese population. Another reason is due to the low number of serotypes covered under PCV7 as observed in the individual studies included for analysis. The proportions of these PCV7-VT are low as well (<4%). The better PCV choice would be PCV10 and PCV13 which is estimated to increase the coverage four-fold.

The GAVI of the Pneumococcal Accelerated Development and Implementation (PneumoADIP) plays a major role to support the financial demand especially for the developing countries towards making the pneumococcal vaccines available to the eligible countries [190]. Asian countries which are GAVI-eligible include Indonesia, Vietnam, Mongolia, North Korea, Nepal, India, Pakistan, and Sri Lanka. Apart from this, useful and effective collaborative networks are especially important to gather essential information of circulating pneumococcal serotypes in the member countries. Several of these networks have been set up, such as SAPNA, a network in India, Nepal, and Sri Lanka for the purpose of conducting standardized IPD surveillance and to investigate the serotype epidemiology and antimicrobial susceptibility profiles of strains circulating in the region and this network is funded by the GAVI, Asian Network for Surveillance of Resistant Pathogens (ANSORP), one of the largest multicountry collaborative network in the world for region-wide surveillance of antimicrobial resistance in Asia [191,192].

The main limitation of this review is the lack of relevant data from quite a number of Asian countries especially in Central Asia, West Asia, and SEA. Overall, only 17 out of the 51 countries in Asia were presented in this review. Although some studies have been reported in these countries (e.g. Indonesia, Vietnam, Philippines, Iran, Yemen, etc) but were then excluded from this review due to incompatibility with our review parameters. Of these, majority are due to isolates used sampled from a prior time frame set (January 2006), carriage isolates, and data corresponding to subset of antibiotic-resistant strains. This will probably underestimate the actual prevalence and serotype distribution in Asia. However, this is to ensure the data reported here reflect the current situation in circulating pneumococcal serotypes involved in pneumococcal diseases. Beside this, the small sample size in a number of studies might result in relatively weak convincing power of the findings stated. In this aspect, several countries have satisfactory sample size, this includes Thailand, Singapore, Malaysia, Bangladesh, Nepal, Turkey, and Taiwan with approximate 200 and more isolates while China, Hong Kong, Korea, Japan, Israel have >800 isolates. Overall, the total isolates included in this review is 12435 (additional three isolates from Pakistan were not included in the analysis) and about half (5236 isolates) were from Israel.

Many of the studies were single-center based or studies examining a certain area of the country/territory. Also, studies which investigated into selected patients group (e.g. meningitis patients or pediatric patients only) may as well misrepresent the serotypes distributions in general. Another problem as similarly pointed out by various authors of the studies included is the low detection of pneumococcal isolates from specimens obtained from the patients, particular those with prior antibiotic used before they have their specimen obtained. This will definitely underestimate the actual number of serotypes and their prevalence. Hence, there is a need for the respective laboratories to better adapt to newer molecular technique such as multiplex PCR [193] which do not always rely on cultured isolates, in contrast to the culture-based Quellung reaction which is currently the gold standard.

Conclusions

In conclusion, the coverage of PCV shows considerable but otherwise related geographical and temporal variations. Surveillance study is still absent in many Asian countries. For countries with previous reported studies but of which recent data is not available, continued surveillance is important to track the possible fluctuations in local serotype epidemiology. In addition, the data is valuable to assist policymakers when considering the potential effectiveness pneumococcal vaccination might have on the population. To evaluate accurately the trend in serotype distribution of a country, establishment of nation-wide surveillance as well as inter-nations collaborative
network are essentially needed. If the vaccine manufacturers are taking their next step to formulate newer vaccine, specifically to the Asian population, serotypes/groups 15, 12F/A, 8, 23A, 11A/D, 2, 10A could be the next potential candidates on the list.

References

1. Bryce J, Boschi-Pinto C, Shibuya K, Black RE (2005) WHO estimates of the causes of death in children. Lancet 365: 1147-1152.

2. Klein JO (1994) Otitis media. Clin Infect Dis 19: 823-833.

3. Mulholland K (1999) Magnitude of the problem of childhood pneumonia. Lancet 354: 590-592.

4. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, et al. (1997) Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 337: 970-976.

5. Pneumococcal conjugate vaccine for childhood immunization—WHO position paper (2007) Wkly Epidemiol Rec 82: 93-104.

6. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, et al. (2007) Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 45: 1225-1233.

7. Jin P, Kong F, Xiao M, Oftadeh S, Zhou F, et al. (2009) First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children. J Infect Dis 200: 1375-1380.

8. Calix JJ, Nahm MH (2010) A new pneumococcal serotype, 11E, has a variably inactivated weCj gene. J Infect Dis 202: 29-38.

9. Hanage WP, Auronen K, Sjöryän R, Herva E, Makela PH, et al. (2004) Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect Immun 72: 75-81.

10. Hausdorff WP, Feikin DR, Klugman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5: 83-93.

11. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R (2006) Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 25: 602-607.

12. Hausdorff WP, Yothers G, Dagan R, Kilpi T, Pelton SI, et al. (2002) Multinational study of pneumococcal disease causing acute otitis media in children. Pediatr Infect Dis J 21: 1008-1016.

13. Rodgers GL, Arguedas A, Cohen R, Dagan R (2009) Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 27: 3802-3810.

14. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, et al. (2009) Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 27: 4891-4904.

15. Moberley SA, Holden J, Tatham DP, Andrews RM (2008) Vaccines for the prevention of pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14: e197-e209.

16. Grijalva CG, Nuorti JP, Arboagast PG, Martin SW, Edwards KM, et al. (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369: 1179-1186.

17. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R (2006) Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 25: 602-607.

18. Mansion PL, Benard C, Callens D, Killar D, Holmberg SH, et al. (2009) Efficacy and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 18: 757-763.

19. Rennels MB, Edwards KM, Keysler HL, Reisinger KS, Hogeran DA, et al. (1998) Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101: 604-611.

20. Destefano F, Pfeifer D, Nohynk H (2008) Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull World Health Organ 86: 373-380.

21. Klein JO (1994) Otitis media. Clin Infect Dis 19: 823-833.

22. Overweg K, Sluijter M, Srodzinski M, de Groot R, Hermans PW (2000) Immune- response to pneumococcal capsular polysaccharide vaccine in African children. FEMS Immunol Med Microbiol 29: 183-185.

23. Begg C, Choong M, Clarke M, Deeks J, Gandek B (2004) Multinational systematic review of conclusions and assumptions. Vaccine 27: 4891-4904.

24. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R (2009) Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 25: 602-607.

25. Calix JJ, Nahm MH (2010) A new pneumococcal serotype, 11E, has a variably inactivated weCj gene. J Infect Dis 202: 29-38.

26. Hanage WP, Auronen K, Sjöryän R, Herva E, Makela PH, et al. (2004) Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect Immun 72: 75-81.

27. Hausdorff WP, Yothers G, Dagan R, Kilpi T, Pelton SI, et al. (2002) Multinational study of pneumococcal disease causing acute otitis media in children. Pediatr Infect Dis J 21: 1008-1016.

28. Rodgers GL, Arguedas A, Cohen R, Dagan R (2009) Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 27: 3802-3810.

29. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, et al. (2009) Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 27: 4891-4904.

30. Moberley SA, Holden J, Tatham DP, Andrews RM (2008) Vaccines for the prevention of pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14: e197-e209.

31. Cameron C, Pebody R (2006) Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill 11: E060202-E060205.

32. Department of Health (2006) Planned changes to the routine Childhood Immunisation Programme.

33. Black S, Shninefeld H, Fireman B, Lewis E, Ray P, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19: 187-195.

34. Isaacman DJ, McIntosh ED, Reinert RR (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14: e197-e209.

35. Grijalva CG, Nuorti JP, Arboagast PG, Martin SW, Edwards KM, et al. (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369: 1179-1186.

36. Farrell DJ, Klugman KP, Pichichero M (2007) Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of the 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 26: 123-128.

37. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. (2010) MMWR Morb Mortal Wkly Rep 59: 253-257.

38. Kaplan SL, Mason EO Jr, Wald ER, Schultz GE, Bradley JS, et al. (2004) Decrease of invasive pneumococcal infections in children among 8 children’s hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113: 443-449.

39. Ruckinger S, van der Linden M, Reinert RR, von Kries R, Burkhart F, et al. (2009) Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27: 4136-4141.

40. Vestrheim DF, Lovoll O, Aaberge IS, Caugant DA, Holby EA, et al. (2008)
Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26: 3277-3281.

41. Dubos F, Marechal I, Husson MO, Courrouble C, Aurel M, et al. (2007) Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch Dis Child 92: 1009-1012.

42. Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D (2008) Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 13: 19962.

43. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrell GJ, et al. (2009) Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49: 205-212.

44. Roche PW, Krause V, Cook H, Barralet J, Coleman D, et al. (2008) Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 32: 18-30.

45. Stephens DS, Zughai SM, Whitney CG, Baughman WS, Barker L, et al. (2005) Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365: 892-893.

46. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-poly saccharide conjugate vaccine. N Engl J Med 348: 1737-1746.

47. Dagan R, Kugman KP (2008) Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 8: 785-795.

48. Joloba ML, Windau A, Bajaksouzian S, Appelbaum PC, Hausdorff WP, et al. (2001) Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis 33: 1489-1494.

49. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, et al. (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354: 1455-1463.

50. Dias R, Canica M (2007) Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol 51: 35-42.

51. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, et al. (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368: 1495-1502.

52. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, et al. (2004) Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 23: 829-833.

53. Casey JR, Pichichero ME (2004) Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 23: 824-828.

54. Pichichero ME, Casey JR (2007) Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era. Pediatr Infect Dis J 26: S12-S16.

55. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, et al. (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196: 1346-1354.

56. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32-41.

57. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998-2003. MMWR Mortal Wkly Rep (2005) 54: 893-897.

58. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, et al. (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294: 2043-2051.

59. Imhol M, Reinert RR, van der Linden M (2010) Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. Int J Med Microbiol 300: 237-247.

60. Lipshitz M (1999) Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5: 336-345.

61. Obaro SK (2000) Confronting the pneumococcus: a target shift or bullet change? Vaccine 19: 1211-1217.

62. Spratt BG, Greenwood BM (2000) Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 356: 1210-1211.

63. Mera R, Miller LA, Fritsche TR, Jones RN (2008) Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 14: 101-107.

64. Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, et al. (2007) Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 26: 461-467.

65. Richter SS, Heilmann KP, Dohm CL, Riahi F, Beekmann SE, et al. (2009) Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 48: e23-e33.

66. Techasensiri C, Messina AF, Katz K, Ahmad N, Huang R, et al. (2010) Epidemiology and evolution of invasive pneumococcal disease caused by multilong resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine inimmunization in Dallas, Texas. Pediatr Infect Dis J 29: 294-300.

67. Pichichero ME, Casey JR (2007) Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298: 1772-1778.

68. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, et al. (2007) Emergence of 19A as virulent and multilong resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 26: 468-472.

69. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998-2005. (2008) MMWR Mortal Wkly Rep 57: 144-148.

70. Normark BH, Otqvist A, Kalmi M, Olsson-Liljeqvist B, Hedlund J, et al. (2001) Changes in serotype distribution may hamper efficacy of pneumococcal conjugate vaccines in children. Scand J Infect Dis 33: 848-850.

71. Beall B, McElstrim MC, Gertz RE Jr, Wedel S, Boxrud DJ, et al. (2006) Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44: 999-1017.

72. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, et al. (2003) Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187: 1424-1432.

73. Enright MC, Spratt BG (1998) A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144: 3049-3060.

74. Bean DC, Klena JD (2005) Characterization of major clones of antibiotic-resistant Streptococcus pneumoniae in New Zealand by multilocus sequence typing. J Antimicrob Chemother 55: 375-378.

75. Shi ZY, Enright MC, Wilkinson P, Griffiths D, Spratt BG (1998) Identification of three major clones of multiply antibiotic-resistant Streptococcus pneumoniae in Taiwanese hospitals by multilocus sequence typing. J Clin Microbiol 36: 3514-3519.

76. Zhou J, Enright MC, Spratt BG (2000) Identification of the major Spanish clones of penicillin-resistant pneumococci via the Internet using multilocus sequence typing. J Clin Microbiol 38: 977-986.

77. Coffey TJ, Berron S, Daniels M, Garcia-Leoni ME, Cercone E, et al. (1996) Multiplication antibiotic-resistant Streptococcus pneumoniae recovered from Spanish hospitals (1988-1994): novel major clones of serotypes 14, 19F and 19A. Microbiology 142: 2747-2757.

78. Crook DW, Spratt BG (1998) Multiple antibiotic resistance in Streptococcus pneumoniae. Br Med Bull 54: 595-610.

79. Enright MC, Fenoll A, Griffiths D, Spratt BG (1999) The three major Spanish clones of penicillin-resistant Streptococcus pneumoniae are the most common clones recovered in recent cases of menigitis in Spain. J Clin Microbiol 37: 3210-3216.
80. Jefferies JM, Smith AJ, Edwards GF, McMenamin J, Mitchell TJ, et al. (2010) Temporal analysis of invasive pneumococcal clones from Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of pneumococcal conjugate vaccine. J Clin Microbiol 48: 87-96.

81. Gertz RE Jr, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, et al. (2003) Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 41: 4194-4216.

82. Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, et al. (2008) Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States. J Infect Dis 197: 1016-1027.

83. Pal R, Moore MR, Plishivtii T, Gertz RE, Whitney CG, et al. (2005) Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192: 1988-1995.

84. Ardanuy C, Rojo D, Fenoll A, Tarrago D, Calatayud L, et al. (2009) Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother 64: 507-510.

85. Cherian T (2007) WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva. Vaccine 25: 6557-6564.

86. Hausdorff WP, Dagan R, Beckers F, Schuerman L (2009) Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27: 7257-7269.

87. Grijalva CG, Edwards KM (2006) Promises and challenges of pneumococcal conjugate vaccines for the developing world. Clin Infect Dis 43: 680-682.

88. Lucero MG, Noyheynk H, Williams G, Tallo V, Simoes EA, et al. (2009) Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J. 28: 455-462.

89. Scott JA (2007) The preventable burden of pneumococcal disease in the developing world. Vaccine 25: 2389-2405.

90. Lin TY, Shah NK, Brooks D, Garcia CS (2010) Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region. Vaccine 28: 7589-7605.

91. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR (2000) The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 30: 122-140.

92. Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30: 100-121.

93. Inohi M, Reinert RR, van der Linden M (2010) Temporal Variations among Invasive Pneumococcal Disease Serotypes in Children and Adults in Germany (1992-2008). Int J Microbiol 2010: 874189.

94. Liu Y, Wang H, Chen M, Sun Z, Zhao R, et al. (2008) Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn Microbiol Infect Dis 61: 256-263.

95. Chen R, Chen Y, Black S, Hao CL, Ding YF, et al. (2010) Antibiotic resistance patterns and serotype distribution in Streptococcus pneumoniae from hospitalized pediatric patients with respiratory infections in Suzhou, China. J Trop Pediatr 56: 204-205.

96. Xue L, Yao K, Xie G, Zheng Y, Wang C, et al. (2010) Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates that cause invasive disease among Chinese children. Clin Infect Dis 50: 741-744.

97. Yao KH, Wang LB, Zhao GM, Zheng YJ, Deng L, et al. (2011) Pneumococcal serotype distribution and antimicrobial resistance in Chinese children hospitalized for lower respiratory infections. Vaccine 29: 2296-2301.

98. Zhang B, Gertz RE Jr, Liu Z, Li Z, Fu W, et al. (2011) Characterization of highly antimicrobial-resistant clinical pneumococcal isolates recovered in a Chinese hospital during 2009-2010. J Med Microbiol.

99. Zhou L, Yu SJ, Gao W, Yao KH, Shen AD, et al. (2011) Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010. Vaccine 29: 7704-7710.

100. Ip M, Nelson EA, Cheuk ES, Sung Ry, Li A, et al. (2007) Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from children hospitalized for acute respiratory illnesses in Hong Kong. J Clin Microbiol 45: 1969-1971.

101. Ho PL, Chiu SS, Ang I, Lau YL (2011) Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae before and after introduction of 7-valent pneumococcal conjugate vaccine, Hong Kong, 1995-2009. Vaccine 29: 3270-3275.

102. Hon KL, Ip M, Lee K, Nelson EA, Shea KH, et al. (2010) Childhood pneumococcal diseases and serotypes: can vaccines protect? Indian J Pediatr 77: 1387-1391.

103. Center for Health Protection Hong Kong (2011) Inclusion of Pneumococcal Vaccine in Childhood Immunisation Programme.

104. Hsieh YC, Chang KY, Huang YC, Lin HC, Ho YH, et al. (2008) Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 52: 2266-2269.

105. Suzuki K, Nishimaki K, Okuyma K, Katoh T, Yasujiha M, et al. (2010) Trends in antimicrobial susceptibility of Streptococcus pneumoniae in the Tokohu district of Japan: a longitudinal analysis from 1998 to 2007. Tokohu J Exp Med 220: 47-57.

106. Hotomi M, Billal DS, Kamide Y, Kanekanu K, Uno Y, et al. (2008) Serotype distribution and penicillin resistance of Streptococcus pneumoniae isolates from middle ear fluids of pediatric patients with acute otitis media in Japan. J Clin Microbiol 46: 3808-3810.

107. Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takanou M, et al. (2010) Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect 138: 61-68.

108. Sakai F, Chiba N, Ono A, Yamagata Murayama S, Ubumaka K, et al. (2011) Molecular epidemiologic characteristics of Streptococcus pneumoniae isolates from children with meningitis in Japan from 2007 through 2009. J Infect Chemother 17: 334-340.

109. Oishi T, Wada A, Chang B, Toyabae S, Uchiyama M (2011) Serotyping and multilocus sequence typing of Streptococcus pneumoniae isolates from the blood and posterior nares of Japanese children prior to the introduction of 7-valent pneumococcal conjugate vaccine. Jpn J Infect Dis 64: 341-344.

110. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, et al. (2008) Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 14: 275-281.

111. Song JH, Baek JY, Cheong HS, Chung DR, Peck KR, et al. (2009) Changes of serotype and genotype in Streptococcus pneumoniae isolates from a Korean hospital in 2007. Diagn Microbiol Infect Dis 63: 271-278.

112. Baek JY, Ko KS, Kim SH, Kang CL, Chung DR, et al. (2011) Comparison of genotypes of Streptococcus pneumoniae serotypes 6A and 6B before and after the introduction of PCV7 vaccination in Korea. Diagn Microbiol Infect Dis 69: 370-375.

113. Hsu LY, Lui SW, Lee JL, Hedzlyn HM, Kong DH, et al. (2009) Adult invasive pneumococcal disease pre- and peri-pneumococcal conjugate vaccine introduction in a tertiary hospital in Singapore. J Med Microbiol 58: 101-104.

114. Jefferies JM, Tee WS, Clarke SC (2011) Molecular analysis of Streptococcus pneumoniae clones causing invasive disease in children in Singapore. J Med Microbiol 60: 750-755.

115. Le CF, Palanisamy NK, Mohd Yusof MY, Sekaran SD (2011) Capsular Serotype and Antibiotic Resistance of Streptococcus pneumoniae Isolates in Malaysia. Plos One 6: e19547.

116. Yasin RM, Zin NM, Hussin A, Nawi SH, Hanaphim SM, et al. (2011) Current trend of pneumococcal serotypes distribution and antibiotic susceptibility pattern in Malaysian hospitals. Vaccine 29: 5688-5693.

117. Sirfengung S, Tribuddhharat C, Comererungsee S, Chansawan T, Kong. J Med Microbiol 60: 750-755.

118. Baggett HC, Peruski LF, Olsen SJ, Thamthiwat S, Rhodes J, et al. (2009) Incidence of pneumococcal bacteraemia requiring hospitalization in rural Thailand. Clin Infect Dis 48: 565-574.

119. Moore CE, Sengduangphachanh A, Thaojakkong T, Sirsouk J, Foster D, et al.
al. (2010) Enhanced determination of Streptococcus pneumoniae serotypes associated with invasive disease in Laos by using a real-time polymerase chain reaction serotyping assay with cerebrospinal fluid. Am J Trop Med Hyg 83: 451-457.

120. Brooks WA, Breiman RF, Goswami D, Hossain A, Alam K, et al. (2007) Invasive pneumococcal disease burden and implications for vaccine policy in urban Bangladesh. Am J Trop Med Hyg 77: 795-801.

121. Saha SK, Naheed A, El Arifeen S, Islam M, Al-Emran H, et al. (2009) Surveillance for invasive Streptococcus pneumoniae disease among hospitalized children in Bangladesh: antimicrobial susceptibility and serotype distribution. Clin Infect Dis 48: S75-S81.

122. Arifeen SE, Saha SK, Rahman S, Rahman KM, Rahman SM, et al. (2009) Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance. Clin Infect Dis 48: S103-S113.

123. Ministry of Health (2008) Report on Pneumococcal & Hib Surveillance - 2005 - 2nd quarter 2008.

124. Williams EJ, Thorson S, Maskey M, Mahat S, Hamaluba M, et al. (2009) Hospital-based surveillance of invasive pneumococcal disease among young children in urban Nepal. Clin Infect Dis 48: S114-S122.

125. Kelly DF, Thorson S, Maskey M, Mahat S, Shrestha U, et al. (2011) The burden of vaccine-preventable invasive bacterial infections and pneumonia in children admitted to hospital in urban Nepal. Int J Trop Dis 15: e17-e23.

126. Shah AS, Knoll MD, Sharma PR, Moisi JC, Kulikarni P, et al. (2009) Invasive pneumococcal disease in Kanti Children’s Hospital, Nepal, as observed by the South Asian Pneumococcal Alliance network. Clin Infect Dis 48: S123-S128.

127. Rajal B, Tandukar S, Adhikari R, Tuladhar NR, Sharma PR, et al. (2010) Antimicrobial susceptibility pattern and serotyping of Streptococcus pneumoniae isolated from Kanti Children Hospital in Nepal. Kathmandu Univ Med J (KUMJ) 8: 164-168.

128. Zaidi AK, Khan H, Lasi R, Mahesar W (2009) Surveillance of pneumococcal meningitis among children in Sindh, southern Pakistan. Clin Infect Dis 48: S120-S135.

129. Al-Yaqoubi M, Elhag K (2011) Serotype Prevalence and Penicillin-susceptibility of Streptococcus pneumoniae in Oman. Oman Med J 26: 43-47.

130. Perdin D, Ay Attiloy Y, Sumerbank B (2010) Ten-year surveillance of invasive Streptococcus pneumoniae isolates in central Turkey prior to the introduction of a conjugate vaccine. J Infect Dev Ctries 4: 560-565.

131. Ceyhan M, Yildirim I, Sheppard CL, George RC (2010) Pneumococcal serotypes causing pediatric meningitis in Turkey: application of a new technology in the investigation of cases negative by conventional culture. Eur J Clin Microbiol Infect Dis 29: 289-293.

132. Ceyhan M, Guler F, Yaman A, Oztkur C, Oksuz L, et al. (2011) Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide. Clin Vaccine Immunol 18: 1028-1030.

133. Kattan R, Abu Rayyan A, Zheiman I, Idkeidek S, Baraghiiti S, et al. (2011) Serotype distribution and drug resistance in Streptococcus pneumoniae, Palestinian Territories. Emerg Infect Dis 17: 94-96.

134. Somchit I, Dagan R, Givon-Lavi N, Potar N, Raiz S, et al. (2011) Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine. Vaccine 29: 4202-4209.

135. Yao K, Shen X, Yul S, Lu Q, Deng L, et al. (2007) Antimicrobial resistance and serotypes of nasopharyngeal strains of Streptococcus pneumoniae in Chinese children with acute respiratory infections. J Int Med Res 35: 253-287.

136. Zhao GM, Black S, Shinefield H, Wang CG, Zhang YH, et al. (2003) Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China. Pediatr Infect Dis J 22: 739-742.

137. Center for Health Protection Hong Kong (19 April 2011). Inclusion of Pneumococcal Vaccine in Childhood Immunisation Programme.

138. Center for Health Protection Hong Kong (April 2011) Recommendations on the Use of 13-valent Pneumococcal Conjugate Vaccine in Childhood Immunisation Programme.
Citation: Le C, Yusof MYM, Sekaran SD (2011) Current Trend in Pneumococcal Serotype Distribution in Asia. J Vaccines Vaccin S2:001. doi:10.4172/2157-7560.S2-001